Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-2218
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2016
Authors
Publisher
American Association for Cancer Research (AACR)